Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 06:00PM GMT
Matthew Kelsey Harrison;Jean
Morgan Stanley, Research Division - Executive Director

Great. Good afternoon. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley, and thanks for joining us for our next session. Very pleased to have BioMarin with us. Briefly before we get started, I need to read a disclosure.

Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately.

For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley representatives.

So with that, I'm very pleased to have 3 members of the management team from BioMarin. J.J. Bienaimé, who's the CEO; Hank Fuchs, who runs R&D; and Brian Mueller, who's the CFO. And J.J., I'm going to turn it over to you to make some opening remarks, and then we'll jump into Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot